Impact of Bariatric Surgery on the Pharmacokinetics Parameters of Amoxicillin
Marina Becker Sales Rocha1, Gilberto De Nucci2, Francisco Ney Lemos3
1Clinical Pharmacology Unit, Drug Research and Development Center, Federal University of Ceara (UFC), Rua Cel. Nunes de Melo 1000 - Rodolfo Teófilo, Fortaleza, Ceará, 60430-275, Brazil. marinabecker@hotmail.com.br.
Background:
Bariatric surgery leads to several anatomo-physiological modifications that may affect pharmacokinetic parameters and consequently alter the therapeutic effect of drugs, such as antibiotics. The pharmacokinetics of oral amoxicillin after Roux-en-Y gastric bypass (RYGB) surgery is unknown.
Objectives:
The objective of this study was to evaluate the impact of bariatric surgery on the pharmacokinetics of amoxicillin.
Methods:
This study was performed as a randomized, open-label, single-dose clinical trial, with two periods of treatment, in which obese subjects (n = 8) received an amoxicillin 500 mg capsule orally before and 2 months after the RYGB surgery. The amoxicillin plasma concentration was determined by liquid chromatography coupled to mass spectrometry (LC-MS/MS).
Results:
After the surgery, the mean weight loss was 17.03 ± 5.51 kg, and mean body mass index (BMI) decreased from 46.21 ± 2.82 to 38.82 ± 3.32 kg/m2. The mean amoxicillin area under the plasma concentration versus time curve from time zero to the time of the last quantifiable concentration (AUC0-tlast) increased significantly (3.5-fold); the maximum plasma concentration (Cmax) increased 2.8-fold after the bariatric surgery. No correlation was found between amoxicillin absorption, BMI, and weight loss percentage.
Conclusion:
The alterations observed in the amoxicillin pharmacokinetics suggest that obese subjects included in this trial had a substantially increase in amoxicillin systemic exposure after RYGB surgery. However, despite this increase, its exposure was lower than the values reported for non-obese volunteers.
Trial Registration:
Identifiers: NCT03588273.
Related Concept Videos
00:54Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
01:06Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
01:19Impact of Groups on Groups
01:10Wave Parameters
01:30Impact
When particles with different initial velocities collide, they induce deformation by applying equal and opposite impulses. At the point of maximum deformation, the particles move together with...